Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancer Phase 1 results for TSR-042 show anti-PD-1 activity Three posters presented during ASCO describe additional analyses of NOVA data Robust demand continues for ZEJULA™ VARUBI® IV PDUFA date is October 25, 2017 VARUBY® oral launch now underway …
The post TESARO Provides Business and Pipeline Update at ASCO Investor Briefing appeared first on ForexTV.
June 04, 2017 at 03:52AM
from Nasdaq NewsFeed
No comments:
Post a Comment